title: Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
authors: Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island2Ocean State Research Institute, Providence Veterans Administration Medical Center, Providence, Rhode Island.
authors: Robert J
authors: RJ
authors: Smith
authors: William R
authors: WR
authors: Hiatt
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000191:economics; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D008078:Cholesterol, LDL / Q000097:blood; D017277:Drug Approval; D005234:Fatty Liver / Q000139:chemically induced; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D009841:Oligonucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D011358:Product Surveillance, Postmarketing; D035583:Rare Diseases / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000924:Anticholesteremic Agents; C473731:BMS201038; D001562:Benzimidazoles; D008078:Cholesterol, LDL; D009841:Oligonucleotides; C524142:mipomersen